Vaxart to add independent director under cooperation deal with stockholder group

Vaxart, Inc

VXRT

0.00

Vaxart reached a cooperation agreement with a stockholder group to end a proxy contest tied to its 2026 annual meeting.
The board will search for an additional independent director within 90 days of the meeting, with the candidate to be mutually agreed.
The stockholder group withdrew director nominations for Daniel P. Houle, Mark Silverberg, DDS, MD, Matthew M. Wallace, MD.
Vaxart formed a Stockholder Engagement Committee, formed a Clinical and Regulatory Affairs Committee, refreshed board committee leadership.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-074576), on July 02, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.